

## RSV Prevention Update - References

*Yvonne Maldonado, MD*

- Ambrose, C. S., Chen, X., & Kumar, V. R. (2014). A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children. *Human vaccines & immunotherapeutics*, 10(10), 2785–2788. <https://doi.org/10.4161/hv.32082>
- Caserta, M. T., O'Leary, S. T., Munoz, F. M., Ralston, S. L., & COMMITTEE ON INFECTIOUS DISEASES (2023). Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. *Pediatrics*, 152(1), e2023061803. <https://doi.org/10.1542/peds.2023-061803>
- Centers for Disease Control and Prevention. (2023). CDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth. *Centers for Disease Control and Prevention, CDC Newsroom; Press Release*. <https://www.cdc.gov/media/releases/2023/p0922-RSV-maternal-vaccine.html>
- Domachowske, J. B., Chang, Y., Atanasova, V., Cabañas, F., Furuno, K., Nguyen, K. A., Banu, I., Kubiak, R. J., Leach, A., Mankad, V. S., Shroff, M., Takas, T., Villafana, T., & Wählby Hamrén, U. (2023). Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease. *Journal of the Pediatric Infectious Diseases Society*, 12(8), 477–480. <https://doi.org/10.1093/jpids/piad052>
- Feltes, T. F., Cabalka, A. K., Meissner, H. C., Piazza, F. M., Carlin, D. A., Top, F. H., Jr, Connor, E. M., Sondheimer, H. M., & Cardiac Synagis Study Group (2003). Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. *The Journal of pediatrics*, 143(4), 532–540. [https://doi.org/10.1067/s0022-3476\(03\)00454-2](https://doi.org/10.1067/s0022-3476(03)00454-2)

Food and Drug Administration. (2023). FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. *Food and Drug Administration*.  
<https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants>

Glezen, W. P., Taber, L. H., Frank, A. L., & Kasel, J. A. (1986). Risk of primary infection and reinfection with respiratory syncytial virus. *American journal of diseases of children* (1960), 140(6), 543–546. <https://doi.org/10.1001/archpedi.1986.02140200053026>

Gonçalves, A., Rocha, G., Guimarães, H., Fernandes, P. C., Proença, E., Oliveira, D., Rocha, P., Quintas, C., Martins, T., Freitas, A., Dias, C. P., & Ramires, A. (2012). Value of Chest Radiographic Pattern in RSV Disease of the Newborn: A Multicenter Retrospective Cohort Study. *Critical care research and practice*, 2012, 861867.  
<https://doi.org/10.1155/2012/861867>

Graham B. S. (2017). Vaccine development for respiratory syncytial virus. *Current opinion in virology*, 23, 107–112. <https://doi.org/10.1016/j.coviro.2017.03.012>

Griffin, M. P., Yuan, Y., Takas, T., Domachowske, J. B., Madhi, S. A., Manzoni, P., Simões, E. A. F., Esser, M. T., Khan, A. A., Dubovsky, F., Villafana, T., DeVincenzo, J. P., & Nirsevimab Study Group (2020). Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. *The New England journal of medicine*, 383(5), 415–425.  
<https://doi.org/10.1056/NEJMoa1913556>

Hall, C. B., Weinberg, G. A., Blumkin, A. K., Edwards, K. M., Staat, M. A., Schultz, A. F., Poehling, K. A., Szilagyi, P. G., Griffin, M. R., Williams, J. V., Zhu, Y., Grijalva, C. G., Prill, M. M., & Iwane, M. K. (2013). Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. *Pediatrics*, 132(2), e341–e348. <https://doi.org/10.1542/peds.2013-0303>

Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A.,

Auinger, P., Griffin, M. R., Poehling, K. A., Erdman, D., Grijalva, C. G., Zhu, Y., & Szilagyi, P. (2009). The burden of respiratory syncytial virus infection in young children. *The New England journal of medicine*, 360(6), 588–598.

<https://doi.org/10.1056/NEJMoa0804877>

Hansen, C. L., Chaves, S. S., Demont, C., & Viboud, C. (2022). Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018. *JAMA network open*, 5(2), e220527. <https://doi.org/10.1001/jamanetworkopen.2022.0527>

IMpact-RSV Study Group, The. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. (1998). *Pediatrics*, 102(3 Pt 1), 531–537.

Langley, G. F., & Anderson, L. J. (2011). Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. *The Pediatric infectious disease journal*, 30(6), 510–517. <https://doi.org/10.1097/INF.0b013e3182184ae7>

McLaughlin, J. M., Khan, F., Schmitt, H. J., Agosti, Y., Jodar, L., Simões, E. A. F., & Swerdlow, D. L. (2022). Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. *The Journal of infectious diseases*, 225(6), 1100–1111. <https://doi.org/10.1093/infdis/jiaa752>

McLaurin, K. K., Farr, A. M., Wade, S. W., Diakun, D. R., & Stewart, D. L. (2016). Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. *Journal of perinatology : official journal of the California Perinatal Association*, 36(11), 990–996. <https://doi.org/10.1038/jp.2016.113>

Muller, W. J., Madhi, S. A., Seoane Nuñez, B., Baca Cots, M., Bosheva, M., Dagan, R., Hammitt, L. L., Llapur, C. J., Novoa, J. M., Saez Llorens, X., Grenham, A., Kelly, E. J., Mankad, V. S., Shroff, M., Takas, T., Leach, A., Villafana, T., & MELODY Study Group (2023). Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. *The New*

*England journal of medicine*, 388(16), 1533–1534.

<https://doi.org/10.1056/NEJMc2214773>

Munjal, I. (2023). Safety and Efficacy of Bivalent RSV Prefusion F Vaccine in Vaccinated Mothers and their Infants. *Centers for Disease Control and Prevention, Pfizer*.

<https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/rsv-pediatric-06-munjal-508.pdf>

PATH. (2023). RSV Vaccine and mAb Snapshot. *Path*.

<https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/>

Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003). Mortality associated with influenza and respiratory syncytial virus in the United States. *JAMA*, 289(2), 179–186. <https://doi.org/10.1001/jama.289.2.179>